Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

The latest trading day saw Gilead Sciences (GILD) settling at $106.67, representing a -0.38% change from its previous close.

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.87, denoting a -1.53% change from the preceding trading day.

Covering a total of 91 developing countries, the cut price drugs will be available to more than 100 million people living with hepatitis C. Controversy won't go away Gilead has a treatment access ...

There has been a lot of discussion about the high price of Gilead's Hepatitis C drug Sovaldi, and a variety of strong opinions expressed. But are agencies around the world asking the right ...

Investors in AbbVie Inc. (NYSE:ABBV) need to pay close attention to the stock based on moves in the options market lately. That ...

Please provide your email address to receive an email when new articles are posted on . Tremfya is the first approved IL-23 inhibitor to offer both IV and fully subcutaneous induction regimens ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...